Three grants given researchers at two centers in Australia will advance work into ways of preserving nerve cells in people with amyotrophic lateral sclerosis (ALS), and other motor neuron diseases. The grants, totaling AU$1.5 million (about $1.1 million), came from FightMND, an Australian nonprofit patient advocacy group. Lezanne…
Search results for:
The National Institutes of Health (NIH) has awarded a $1.9 million grant to University of Missouri (MU) researchers to study ways of preserving essential functions like swallowing and breathing in people with amyotrophic lateral sclerosis (ALS) and other motor neuron diseases. This four-year grant was awarded to…
Novus Therapeutics has acquired Anelixis Therapeutics and its portfolio, including the antibody AT-1501, a potential treatment for amyotrophic lateral sclerosis (ALS) that the company is planning to move into a Phase 2 clinical trial for ALS and other diseases. AT-1501 is an antibody against a…
Microsoft opened its 2014 Super Bowl ad with the question: “What is technology?” As Steve Gleason, an ex-New Orleans Saints safety later diagnosed with amyotrophic lateral sclerosis (ALS), spoke about the power of technology, videos rolled of doctors manipulating 3D X-rays, a blind man painting,…
IPL344, Immunity Pharma‘s investigational therapy for amyotrophic lateral sclerosis (ALS), has a positive safety and tolerability profile and slows disease progression by about 50%, according to interim results from a small Phase 1/2a clinical trial. The company said it now is planning a placebo-controlled trial to evaluate IPL344…
Helixmith has selected Worldwide Clinical Trials to run a planned Phase 2 study of Engensis (VM202), its potential gene therapy for amyotrophic lateral sclerosis (ALS), according to a company press release. Engensis consists of a circular piece of DNA called a plasmid that carries instructions…
PrimeC is safe and well-tolerated for the treatment of amyotrophic lateral sclerosis (ALS) and shows potential to slow disease progression and lung function decline, according to interim results from a Phase 2a clinical trial. Given these results, developer NeuroSense Therapeutics will continue investigating PrimeC with additional analysis…
Newly developed compounds derived from ebselen could be used to treat some types of amyotrophic lateral sclerosis (ALS), a recent study suggests. The study, “Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis,” was published in EBioMedicine. About a fifth of familial…
The ALS Association and I AM ALS have opened a petition calling for the earliest possible approval of Amylyx’s experimental oral treatment AMX0035, after a Phase 2/3 trial found the therapy to be safe and to slow functional decline in amyotrophic lateral sclerosis (ALS) patients with rapidly progressing disease. Addressing the…
Younger cycad seeds can contain more toxins than older seeds, and their widespread consumption by people on occupied Guam during World War II could be the environmental origin of the rare sporadic amyotrophic lateral sclerosis (ALS) cluster found there, according to a recent study. Guam residents emerged from their wartime…